Clinical Trials on Alzheimer's Disease Conference

Key Takeaways From a Study of FUS in Early AD Dementia: Ali Rezai, MD

November 28, 2021

The executive chair at the Rockefeller Neuroscience Institute at West Virginia University shed light on early data from a small sample of patients with early Alzheimer disease who underwent focused ultrasound treatment. [WATCH TIME: 5 minutes]

Next Steps, Future Development of FUS Technology in Alzheimer Disease: Ali Rezai, MD

November 22, 2021

The executive chair of the Rockefeller Neuroscience Institute at West Virginia University discussed the potential of focused ultrasound for patients with AD, as well as key takeaways for clinicians from a recent study. [WATCH TIME: 5 minutes]

Evaluating Early Data on Focused Ultrasound for Patients With Alzheimer Disease

November 19, 2021

Ali Rezai, MD, executive chair at the Rockefeller Neuroscience Institute at West Virginia University, outlined early data from a clinical trial utilizing focused ultrasound to open the blood-brain barrier in patients with mild AD.

Neflamapimod Displays Robust Efficacy in Pure Lewy Body Dementia Pathology

November 19, 2021

The magnitude of neflamapimod’s effect on several efficacy measures proved to be consistent with the mechanism of action and prior preclinical data, with p-tau181 data suggesting a stronger effect on nonmixed Lewy body pathology.